Literature DB >> 34453963

Epidemiology and risk-stratification of NAFLD-associated HCC.

George N Ioannou1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is projected to become the leading cause of hepatocellular carcinoma (HCC) in many countries. Many risk factors for NAFLD are also independently associated with HCC, including obesity, diabetes, Hispanic ethnicity and genetic polymorphisms in PNPLA3, TM6SF2, GCKR, MBOAT7 and HSD17B13. Steatosis-related lipotoxicity and oxidative DNA damage can induce hepatocarcinogenesis. These factors may explain the association between NAFLD and HCC, especially in the absence of cirrhosis. In fact, NAFLD/NASH is a leading cause of HCC in the absence of cirrhosis. Identifying patients with pre-cirrhotic NAFLD who have a high enough HCC risk to justify HCC screening represents one of the greatest clinical challenges in NAFLD. Validated models that combine multiple risk factors and fibrosis stage into "HCC risk calculators" are not yet available for patients with NAFLD. Development of such tools would enable risk stratification, identification of high-risk patients even in the absence of cirrhosis, and individualised (risk-based) surveillance strategies. Published by Elsevier B.V.

Entities:  

Keywords:  Fatty liver; NAFLD; hepatocellular carcinoma; liver cancer; precision screening; prediction model; risk stratification; screening; steatohepatitis; surveillance

Mesh:

Year:  2021        PMID: 34453963     DOI: 10.1016/j.jhep.2021.08.012

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  30 in total

Review 1.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

2.  Improved Ultrasound Attenuation Estimation with Non-uniform Structure Detection and Removal.

Authors:  Ping Gong; Chengwu Huang; U-Wai Lok; Shanshan Tang; Wenwu Ling; Chenyun Zhou; Lulu Yang; Kymberly D Watt; Matthew Callstrom; Shigao Chen
Journal:  Ultrasound Med Biol       Date:  2022-08-26       Impact factor: 3.694

3.  Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma.

Authors:  Xiaodong Wang; Jing Qian; Ninghua Yao; Christine Pocha; Koo Jeong Kang; Roberta Angelico; Guodong Zhu
Journal:  Ann Transl Med       Date:  2022-05

4.  Exosomes From Cancer-Associated Mesenchymal Stem Cells Transmit TMBIM6 to Promote the Malignant Behavior of Hepatocellular Carcinoma via Activating PI3K/AKT Pathway.

Authors:  Chuzhi Shang; Mi Ke; Lin Liu; Cong Wang; Yufang Liu; Xin Zheng
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

5.  Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities.

Authors:  Kouichi Miura; Hiroshi Maeda; Naoki Morimoto; Shunji Watanabe; Mamiko Tsukui; Yoshinari Takaoka; Hiroaki Nomoto; Rie Goka; Kazuhiko Kotani; Hironori Yamamoto
Journal:  World J Gastrointest Pathophysiol       Date:  2022-05-22

Review 6.  Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.

Authors:  Yong-Yu Yang; Li Xie; Ning-Ping Zhang; Da Zhou; Tao-Tao Liu; Jian Wu
Journal:  Acta Pharmacol Sin       Date:  2022-02-21       Impact factor: 7.169

Review 7.  Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?

Authors:  Francesco Paolo Russo; Alberto Zanetto; Elisa Pinto; Sara Battistella; Barbara Penzo; Patrizia Burra; Fabio Farinati
Journal:  Int J Mol Sci       Date:  2022-01-02       Impact factor: 5.923

8.  The changing epidemiology of hepatocellular carcinoma in Greece.

Authors:  George E Markakis; Andreas Koulouris; Maria Tampaki; Evangelos Cholongitas; Melanie Deutsch; George V Papatheodoridis; John Koskinas
Journal:  Ann Gastroenterol       Date:  2021-12-06

Review 9.  HSD17B13: A Potential Therapeutic Target for NAFLD.

Authors:  Hai-Bo Zhang; Wen Su; Hu Xu; Xiao-Yan Zhang; You-Fei Guan
Journal:  Front Mol Biosci       Date:  2022-01-07

10.  Inflammatory Cytokines, Adipocytokines, and Th17/Treg Balance in Patients with Nonalcoholic Fatty Liver Disease following Administration of Dahuang Zhechong Pills.

Authors:  Xiaohua Duan; Jianlin Lv; Hebei Jiang; Kefei Zheng; Yulin Chen
Journal:  Genet Res (Camb)       Date:  2022-01-07       Impact factor: 1.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.